EGF-stimulated tyrosine phosphorylation of p185neu: a potential model for receptor interactions.
about
Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor familyAppearance of heparin-binding EGF-like growth factor in wound fluid as a response to injuryA hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factorTyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinasesThe cellular response to neuregulins is governed by complex interactions of the erbB receptor familyDiversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactionsInsulin receptor is phosphorylated in response to treatment of HepG2 cells with insulin-like growth factor Ic-Kit-kinase induces a cascade of protein tyrosine phosphorylation in normal human melanocytes in response to mast cell growth factor and stimulates mitogen-activated protein kinase but is down-regulated in melanomas.Spk1, a new kinase from Saccharomyces cerevisiae, phosphorylates proteins on serine, threonine, and tyrosine.A chimeric EGF-R-neu proto-oncogene allows EGF to regulate neu tyrosine kinase and cell transformation.Intermolecular transphosphorylation between insulin receptors and EGF-insulin receptor chimerae.The epidermal growth factor receptor and the product of the neu protooncogene are members of a receptor tyrosine phosphorylation cascade.Activation of Neu (ErbB-2) mediated by disulfide bond-induced dimerization reveals a receptor tyrosine kinase dimer interface.Experimental approaches to hypothetical hormones: detection of a candidate ligand of the neu protooncogene.A subdomain in the transmembrane domain is necessary for p185neu* activation.Novel luciferase-based reporter system to monitor activation of ErbB2/Her2/neu pathway noninvasively during radiotherapy.Extracellular domains drive homo- but not hetero-dimerization of erbB receptorsCombination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumor and anti-angiogenic responses in vitro and in vivoHeterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: a mechanism of interreceptor kinase activation and transphosphorylation.Profiling receptor tyrosine kinase activation by using Ab microarrays.Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors.Protein quantification from complex protein mixtures using a proteomics methodology with single-cell resolution.Ductal adenocarcinoma of the pancreas: Expression of growth factor receptors, oncogenes and suppressor genes, and their relationship to pathological features, staging and survival.Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo.Expression of functional human EGF receptor on murine bone marrow cells.Epidermal growth factor stimulates substrate-selective protein-tyrosine-phosphatase activitySynergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice.Regulation of phosphorylation of the c-erbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cellsThe carboxy-terminal domains of erbB-2 and epidermal growth factor receptor exert different regulatory effects on intrinsic receptor tyrosine kinase function and transforming activityTyrosine phosphorylation is an early and specific event involved in primary keratinocyte differentiationp185c-neu and epidermal growth factor receptor associate into a structure composed of activated kinasesOncogenic activation of p185neu stimulates tyrosine phosphorylation in vivoRegulation of epidermal growth factor receptor signaling by endocytosis and intracellular traffickingC-erbB-2 immunostaining: problems with interpretationSynthetic phosphopeptide immunogens yield activation-specific antibodies to the c-erbB-2 receptor.Antiserum raised against a synthetic phosphotyrosine-containing peptide selectively recognizes p185neu/erbB-2 and the epidermal growth factor receptor.Mutations affecting conserved cysteine residues within the extracellular domain of Neu promote receptor dimerization and activation.Characterization of a neu/c-erbB-2 protein-specific activating factorAgonistic antibodies stimulate the kinase encoded by the neu protooncogene in living cells but the oncogenic mutant is constitutively active
P2860
Q24309266-DDCD76AC-EBC9-40E0-8175-73A155D4118BQ24314750-96CBFE2F-70F9-4C25-BEC7-8D408EA41443Q24563035-7296EFE6-A66D-40CA-8BDE-6D16C13BAD44Q24648517-E70A9814-9314-4AE7-A221-901AB78206BCQ24802950-ABE77B1F-357E-4C38-B802-B7410F7A0997Q28609130-EE9D9FD9-7C04-4858-8C62-367CD869A4FDQ28609149-03124427-0AB1-4398-BDCE-9A1C3222828DQ28677969-B325895F-6571-401D-A01D-AE5DE9662DDFQ30451017-1999FB6F-5576-44AA-BE35-0EF63EB58726Q30852323-95F8883E-95CE-4F64-90AE-0061A62A9448Q33557958-4F6FE84E-9E73-4BB2-A5C6-58C6B7AF6171Q33584471-55968EF7-4E2F-4A71-A77D-4EAC79A196EEQ33734567-DA7FAEC7-85AE-4E1C-9B11-85F2CD5B78D5Q33778555-516BBDF6-8B1E-49B2-962F-476BE48FF83FQ33852935-2FA95223-2879-4F3C-918E-7CA3E642119DQ33937484-1E8E0E7A-D128-485B-B3FF-D2D3D4946E60Q34424593-DF0C04A5-BB82-4C4B-AFD6-4ABCE79BC01EQ34488149-EF56BB62-D84F-4754-90FF-BFB6534FFDCCQ34787422-B2E10248-42F6-4E91-A7B0-9AAC625B1ACDQ35054357-1354BD49-13FF-4043-900D-B908C0FE7FE7Q35234519-9F532CC5-EF07-4501-BC1E-5076F2ABECB4Q35774089-277B83A2-2252-4BDA-9277-1BDC5FB3E849Q35882686-2E349820-91E9-4501-AFEB-020E11ACF4B3Q36142444-B79CCBA0-1BB9-4694-865C-EAAF27E353C4Q36388501-8B3342D6-6A35-4AFC-BCC8-946D89455592Q36428262-500FD75A-979F-47B1-98C0-C6761DA391BEQ36484874-9960C3A7-933E-4B33-AFF7-A1BEF26504F0Q36563002-CFAE5F4B-E3A6-4785-AFE0-5ABA7D8A2280Q36684680-68043D75-512B-4A6F-B937-3FBA62499294Q36710439-E8793B18-DB51-4795-AC37-DC1D8F92D4BDQ36721520-9BCADDCC-F320-4634-8911-F2E8A7D250C5Q36833642-CD3A2218-61C4-4A03-9FB5-16EDEE26A06BQ36845863-DB3E853B-F54B-48EC-B0D3-C22A66CF28A4Q37074180-D84CD645-CDD5-4AC2-863B-8522B4F687D3Q37104860-F1514D31-0D4F-46E0-84BB-54F05FB381F8Q37280359-F37D1B9B-3ACF-4DDA-8F08-9D9FAB2AE3D7Q37333311-D9B4B6BD-4219-4D78-9147-6FB93845A69DQ37375814-C57648E4-78E5-41A9-94A3-A7D7EFC8855BQ37598840-50C688D7-A8D4-4409-863A-E00A4B1533A9Q37730041-0472A4BF-8861-4E89-83DD-EBA41A04004F
P2860
EGF-stimulated tyrosine phosphorylation of p185neu: a potential model for receptor interactions.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
1988年论文
@zh
1988年论文
@zh-cn
name
EGF-stimulated tyrosine phosph ...... del for receptor interactions.
@ast
EGF-stimulated tyrosine phosph ...... del for receptor interactions.
@en
type
label
EGF-stimulated tyrosine phosph ...... del for receptor interactions.
@ast
EGF-stimulated tyrosine phosph ...... del for receptor interactions.
@en
prefLabel
EGF-stimulated tyrosine phosph ...... del for receptor interactions.
@ast
EGF-stimulated tyrosine phosph ...... del for receptor interactions.
@en
P2860
P1433
P1476
EGF-stimulated tyrosine phosph ...... del for receptor interactions.
@en
P2093
P2860
P304
P407
P577
1988-04-01T00:00:00Z